These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31092464)

  • 1. The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer.
    Vogel C; Malter W; Morgenstern B; Ludwig S; Vehreschild JJ; Hamacher S; Mallmann P; Kirn V; Thangarajah F
    Anticancer Res; 2019 May; 39(5):2647-2659. PubMed ID: 31092464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.
    Ongaro E; Gerratana L; Cinausero M; Pelizzari G; Poletto E; Giangreco M; Andreetta C; Pizzolitto S; Di Loreto C; Minisini AM; Mansutti M; Russo S; Fasola G; Puglisi F
    Future Oncol; 2018 Apr; 14(9):849-859. PubMed ID: 29527957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.
    Berghuis AMS; van Deurzen CHM; Koffijberg H; Terstappen LWMM; Sleijfer S; IJzerman MJ
    Breast Cancer Res Treat; 2019 Jun; 175(2):451-458. PubMed ID: 30756285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
    Ba JL; Liu CG; Jin F
    Asian Pac J Cancer Prev; 2014; 15(21):9233-9. PubMed ID: 25422206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
    Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
    Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
    Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X
    Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
    Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
    Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients.
    Nguyen TH; Nguyen VH; Nguyen TL; Qiuyin C; Phung TH
    Biomed Res Int; 2019; 2019():7391237. PubMed ID: 31583246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
    Kaidar-Person O; Meattini I; Jain P; Bult P; Simone N; Kindts I; Steffens R; Weltens C; Navarria P; Belkacemi Y; Lopez-Guerra J; Livi L; Baumert BG; Vieites B; Limon D; Kurman N; Ko K; Yu JB; Chiang V; Poortmans P; Zagar T
    Breast Cancer Res Treat; 2018 Jan; 167(2):479-483. PubMed ID: 28975433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
    Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
    Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
    Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
    Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
    Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
    Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis.
    Yao ZX; Lu LJ; Wang RJ; Jin LB; Liu SC; Li HY; Ren GS; Wu KN; Wang DL; Kong LQ
    Med Oncol; 2014 Jan; 31(1):798. PubMed ID: 24307349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution.
    Chen R; Qarmali M; Siegal GP; Wei S
    Mod Pathol; 2020 Dec; 33(12):2499-2506. PubMed ID: 32620918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer.
    Erdem GU; Altundag K; Ozdemir NY; Sahin S; Demirci NS; Karatas F; Bozkaya Y; Aytekin A; Tasdemir V; Aslan AC; Sever AR; Zengin N
    J BUON; 2017; 22(2):365-376. PubMed ID: 28534357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
    Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
    Rao PS; Labhart M; Mayhew SL; Thirumala S; Rao US
    Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.